Date: 3/7/2022

ARIZONA STATE UNIVERSITY IACUC ANNUAL REVIEW

l.	Currently approved protocol					
	Protocol Number: 21-1824R					
	Protocol Title: Comparison of transdermal, intravenous and oral delivery of bioactive compounds and drug					
for b	browning white adipose tissue and evaluate their effects on obesity, atherosclerosis, fatty liver disease and diabetes					
Principal Investigator:						
	Funded Unfunded					
	We have both funded and unfunded projects under this animal protocol.					
II.	Status of Project					
	A. Were the animal activities conducted?					
	i. Xes, they were conducted. If yes,					
	1. Were there any significant animal welfare issues (morbidity or mortality, complications, etc.)					
	encountered over the past 12 months?					
	a. Yes. Describe (include the problem, approximate number of animals affected, and					
	resolution).					
	One mouse had hydrocephalus, the mouse was euthanized immediately. One mouse had dermatitis, and it received treatment.					
	b. No. Proceed to item II B.					
	2. Were all unanticipated welfare issues reported?					
	a. X Yes. Proceed to item II B.					
	b. No. Describe. Proceed to item II B when completed.					
	ii. No, they were not conducted. If the protocol will be terminated, complete the Final Review form.1. If the protocol will remain active, why were animal activities not conducted?					
	Proceed to Section II B.					
	B. Have there been any recent findings, either from this study or a related study that would change the					
	planned use of animals?					
	• Species Used					
	Animal Numbers					
	 Procedures 					
	Criteria to Measure/Monitor Pain or Distress					
	Alternatives to Painful Procedures					
	• Restraint					
	 Amelioration and Control of Painful Procedures 					
	 Estimation of Potential Postoperative/Intervention Pain 					
	 Preoperative/Postoperative/Chronic Care 					
	Euthanasia/Disposition of Animals					
	Animal Care and/or Use Sites					
	i. Yes. Complete a separate Request for Changes form describing all proposed changes as well as					
	the scientific rationale for these changes. Proceed to item III.					
	ii No Proceed to item III					

III. Updated Information

A.	Did the pain status stated on the protocol remain appropriate for the procedures performed?						
	i. 🛚	Yes. Proceed to item III B. No. If no, please describe: Proceed to item III B when completed.					
В.	. Has there been new funding added to the project?						
	i. 🛚	Yes. Provide new grant(s) information: Granting Agency: AHA Title: Browning WAT inhibits at berosclerosis ASU Proposal or Award number					
		No.					

IV. Progress Report (for research or teaching protocols only)

Provide a statement on progress under this protocol over the past 12 months. Include any presentations or publications that have resulted from this protocol during the past 12 months.

We have conducted several animal studies, that include transdermal delivery for browning white adipose tissue. Oral administration for enhancing oral bioavailability, and target specificity studies. Mice paper is under writing. One experimental biology 2022 abstract has been accepted, the abstract title is Biocompatible and biodegradable nanoparticles for enhancing solubility and bioavailability of trans-resveratrol.

V. Personnel

All personnel who work with animals are required to have animal care training within the last four years. ASU IACUC training modules can be completed at https://asu.co1.qualtrics.com/ife/form/SV b2b2XRXRRs1309f. Personnel are required to have Level III training certification on file with the IACUC office in order to perform procedures independently (without supervision). See the IACUC web site https://researchintegrity.asu.edu/animals/training) for more information on training and Level III forms.

* Procedures other than husbandry, handling, or behavioral testing MUST be performed under supervision unless the person is Level III certified to conduct the procedure independently. Personnel are not Level III certified until the IACUC has reviewed and approved the Level III training documentation. The PI is responsible for ensuring that personnel who are not Level III certified are supervised at all times.

A. List the names, titles, affiliations, and roles of ALL persons currently involved in the research or teaching activity.

			Role in Protocol			
				What activities will each person be allowed to		
				perform independently	Species with which	FOR IACUC USE ONLY
		<u>ASURITE</u>	What activities will each	(including appropriate	individual will have	
		name	person perform on live	Level 3 certification*) at	direct contact	
			animals ONLY while under	the time of protocol	("none "all" or list	Training
<u>Name</u>	<u>Title</u>		direct supervision?	submission?	species)	Confirmation
						8/2020 Basics
	PI		All	All	All	10/2020 Rodents

				OHSP
Postdoc	All	All	All	1/2021 OHSP
postdoc	All	All	All	8/2021 OHSP
PhD student	All	All	All	8/2021 OHSP
	Oral glucose tolerance, euthanize mice, IVIS	Basic and standard		7/2021 OHSP
Undergraduate student	imaging, transdermal delivery	handling and body weight and composition measures	All	
	Oral glucose tolerance, euthanize mice, IVIS	Basic and standard		6/2021 OHSP
Undergraduate student	imaging, transdermal delivery	handling and body weight and composition measures	All	
	Oral glucose tolerance, euthanize mice, IVIS	Basic and standard		7/2021 OHSP
Undergraduate student	imaging, transdermal delivery	handling and body weight and composition measures	All	

- B. If any of the above listed personnel are new to the protocol, describe their years of experience with all listed species and procedures they will be conducting under this protocol. For procedures for which they are not yet trained, but will likely be trained to do during the activity period of this protocol, provide a description of who will provide such training:
- C. List the names of any individuals no longer involved with the research (these individuals will be removed from the protocol and DACT will be notified):

VI. Certification

By signing this report, I certify that, to the best of my knowledge, the information included herein is accurate and complete. I understand that continued animal use past the scheduled termination date of the protocol requires IACUC approval. I also understand that should the animal use under this protocol require ANY change from that stated in the protocol, prior approval by the IACUC is required.

		03-07-2022
Principal Investigator's Signature	Date	

FOR IACUC USE ONLY Annual Review Determination

ANNUAL REVIEW APPROVAL SIGNATURES:	
Chair, IACUC (or Designee)	Date
Attending Veterinarian (or Designee)	Date
IACUC Member	